- Services
- Therapeutic Areas
- Model Systems
- In Vitro
- In Vivo
- Technologies
- Service Type
- About Us
- Our Science
- Start Your Study Now
Presented by: Dr. Rajendra Kumari, Crown BioscienceProstate cancer is a highly heterogeneous disease, with extremely complex biological, hormonal, and molecular characteristics. Recently, our understanding of the biology of prostate cancer has improved, resulting in the development of several new targeted therapies such as abiraterone (Zytiga®) and enzalutamide (Xtandi®). However, there remains a substantial lack of preclinical models that adequately represent the spectrum of benign, latent, aggressive, and metastatic forms of human prostate cancer. This shortage of relevant preclinical models presents a significant challenge for identifying and developing further targeted prostate cancer therapies and overcoming drug resistance.
Patient-derived xenografts (PDX) are an improved predictive preclinical model, demonstrating to be more clinically relevant through better representation of human heterogeneity. Prostate PDX models have historically been challenging to develop due to a slower growth timeline than other cancer types. This webinar will address the challenges in developing prostate cancer PDX models and discuss newly validated models. We will highlight recent data and discuss how these models can be applied to improve preclinical efficacy studies.
After receiving her Ph.D from the University of Leicester in Molecular Pharmacology, Rajendra joined the lab of Prof. Sue Watson as a postdoctoral fellow in the Division of Pre-clinical Oncology, School of Clinical Sciences, University of Nottingham (UoN). In 2005, Rajendra took the role of Project and Business Manager of the Preclinical Oncology Services (PRECOS) contract research business unit where she built up and managed the portfolio of preclinical in vitro and in vivo projects, products, team and clients, as well as marketing and developing the commercial processes of PRECOS.
Rajendra’s expertise in cancer cell biology and model development helped to build PRECOS, develop an academic career as a lecturer in the School of Clinical Sciences, as well as co-founding the Ex Vivo Pharmacology Centre of Excellence (UoN), which recapitulates the tumor microenvironment through use of clinically-derived tissue. Rajendra was pivotal in the growth of the business unit and commercialization of research which led to the establishment of the spinout of PRECOS Ltd in 2010, acting as Chief Operations Officer, Board Director and co-founder, until merger with Crown Bioscience in July 2013 and now acts as GM/CSO for CBUK leading the scientific strategy, R&D, and operations for CrownBio’s European site in Loughborough.
Rajendra is a member of the American Association of Cancer Research, British Association of Cancer Research, the NC3Rs Cancer Research Advisory Group, and has authored over 40 abstracts and publications.
